^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    SCGB2A2 (Secretoglobin Family 2A Member 2)

    i
    Other names: SCGB2A2, Secretoglobin Family 2A Member 2, UGB2, Prostatic Steroid Binding Protein 1, Mammaglobin 1, Mammaglobin-A, MGB1, Prostatic Steroid-Binding Protein 1, Mammaglobin A, Mammaglobin-1, MGC71974, SCGB2A2, PSBP1
    Associations

    News

    Trials
    18d
    Neoadjuvant endocrine treatment plus mammaglobin-A DNA vaccine induces antitumor immune responses in the primary tumor and peripheral blood of breast cancer patients: Insights from a phase 1b clinical trial. (PubMed, Cancer Immunol Res)
    In addition, post-vaccination tumor samples exhibited close spatial interactions between cytotoxic CD8+ T cells (CTL) and Mam-A+ tumor cells and between CTL and antigen-experienced CD4+ T cells. Together, these results suggest that Mam-A DNA vaccination elicits both systemic and intratumoral antitumor immune responses.
    P1 data • Journal
    |
    ER (Estrogen receptor) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule) • SCGB2A2 (Secretoglobin Family 2A Member 2)
    |
    ER positive
    |
    mammaglobin-A DNA vaccine
    28d
    Alterations in the transcriptional profile of genes in tumors as a prerequisite for personalization of treatment in breast cancer patients (PubMed, Arkh Patol)
    Comparative mRNA expression analysis confirms that a short preoperative course of aromatase inhibitors induces a more potent and uniform molecular response, characterized by profound suppression of proliferation and complete inhibition of estrogen-dependent signaling. Tamoxifen therapy is also effective but results in less pronounced suppression of key targets and, crucially, may be accompanied by early activation of the MYC oncogene, a potential marker for resistance development.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • PTEN (Phosphatase and tensin homolog) • BCL2 (B-cell CLL/lymphoma 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1) • CCNE1 (Cyclin E1) • FGFR4 (Fibroblast growth factor receptor 4) • BIRC5 (Baculoviral IAP repeat containing 5) • TYMS (Thymidylate Synthetase) • AURKA (Aurora kinase A) • FOXA1 (Forkhead Box A1) • PPP2R2A (Protein Phosphatase 2, Regulatory Subunit B, Alpha) • PTTG1 (PTTG1 Regulator Of Sister Chromatid Separation, Securin) • BAG1 (BAG Cochaperone 1) • EMSY (EMSY Transcriptional Repressor BRCA2 Interacting) • GATA3 (GATA binding protein 3) • KRT5 (Keratin 5) • MMP11 (Matrix Metallopeptidase 11) • MYBL2 (MYB Proto-Oncogene Like 2) • SFRP1 (Secreted frizzled related protein 1) • TMEM45B (Transmembrane Protein 45B) • ANLN (Anillin Actin Binding Protein) • CCNB1 (Cyclin B1) • SCGB2A2 (Secretoglobin Family 2A Member 2) • ZNF703 (Zinc Finger Protein 703)
    |
    HER-2 negative • HER-2 expression
    |
    tamoxifen • letrozole • anastrozole
    2ms
    Peripheral Serum From Breast Implant-Exposed Patients Decreases Breast Cancer Cell Viability: Evidence for Immunosurveillance. (PubMed, Aesthet Surg J)
    These findings support the hypothesis that the inflammatory response to breast implants may increase breast cancer immunosurveillance, although significantly more work is needed to confirm a mechanism. Level of Evidence: 3 (Therapeutic).
    Journal
    |
    ER (Estrogen receptor) • MUC1 (Mucin 1) • SCGB2A2 (Secretoglobin Family 2A Member 2)
    2ms
    Machine learning-based identification of kbhb-affected tumor cell subsets as prognostic and therapeutic targets in breast cancer. (PubMed, J Transl Med)
    Kbhb influences breast cancer heterogeneity, with SCGB2A2 + neoplastic cells serving as valuable prognostic indicators. Targeting these cells may improve therapeutic outcomes. Our model also supports machine learning-guided drug discovery for metabolically vulnerable subpopulations.
    Journal • IO biomarker
    |
    SCGB2A2 (Secretoglobin Family 2A Member 2)
    7ms
    First case report of immune checkpoint inhibitor therapy to treat secretory carcinoma. (PubMed, Ther Adv Med Oncol)
    The patient received five cycles of toripalimab and pemetrexed plus carboplatin at a local hospital without treatment-related adverse events. Tumor regression was scarcely observed in the surgically resected specimens. This patient was the fifth reported case of primary SC of the lung and the first case of SC treated with immune checkpoint inhibitor therapy that was evaluated in terms of comprehensive safety and efficacy.
    Journal • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1) • ETV6 (ETS Variant Transcription Factor 6) • NKX2-1 (NK2 Homeobox 1) • NAPSA (Napsin A Aspartic Peptidase) • SCGB2A2 (Secretoglobin Family 2A Member 2)
    |
    carboplatin • Loqtorzi (toripalimab-tpzi) • pemetrexed
    8ms
    Practical pathological methods for reliable diagnosis of secretory carcinomas of the salivary gland. (PubMed, Discov Oncol)
    However, combining mammaglobin and S-100 could be particularly useful in diagnosing SC. This practical method will contribute to accurate diagnosis of SCs, while saving time in daily clinical practice.
    Journal
    |
    NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6) • SCGB2A2 (Secretoglobin Family 2A Member 2) • TFAM (Transcription Factor A, Mitochondrial)
    10ms
    A Rare Case of Mammary Analogue Secretory Carcinoma Localized in the Submandibular Gland. (PubMed, Turk Arch Otorhinolaryngol)
    By presenting this case report, we aimed to add a new case to the already limited number of submandibular gland localized MASC cases in the literature and contribute to the pool of knowledge on this subject. MASC should be considered especially in cases with submandibular gland localization in which the FNAB result is reported as atypia of uncertain significance.
    Journal
    |
    SCGB2A2 (Secretoglobin Family 2A Member 2)
    10ms
    Breast Implants Elicit Local and Systemic Immune Response: Evidence for Breast Cancer Immunosurveillance. (PubMed, Plast Reconstr Surg)
    This is the first study to demonstrate that periimplant inflammation extends beyond the implant capsule to the breast parenchyma. Women with breast implants have more activated B cells in the breast parenchyma and elevated antibody responses to breast cancer antigen.
    Journal
    |
    ER (Estrogen receptor) • MUC1 (Mucin 1) • SCGB2A2 (Secretoglobin Family 2A Member 2)
    12ms
    Salivary gland secretory carcinoma with an ETV6::RET fusion: A case report. (PubMed, Biomed Rep)
    Thus, salivary gland SC with an ETV6::RET fusion may show infiltrative growth and may be more aggressive compared with salivary gland SC with an ETV6::NTRK3 fusion, which is often associated with an indolent clinical course. Therefore, confirmation of the genetic profile of SC is crucial for the prediction of patient prognosis and administration of an effective therapeutic course.
    Journal
    |
    RET (Ret Proto-Oncogene) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6) • ANO1 (Anoctamin 1) • GATA3 (GATA binding protein 3) • SCGB2A2 (Secretoglobin Family 2A Member 2)
    |
    RET fusion
    1year
    Role of Ancillary Techniques in the Differential Diagnosis of Salivary Gland Carcinomas. (PubMed, APMIS)
    The use of molecular techniques for the diagnosis of MEC (MAML2), SC (ETV6), adenoid cystic carcinoma (MYB), and AcCC (NR4A3) is discussed. We highlight the role of commonly available antibodies for the histological classification of SGC.
    Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ETV6 (ETS Variant Transcription Factor 6) • NR4A3 (Nuclear receptor subfamily 4 group A member 3) • SOX10 (SRY-Box 10) • ANO1 (Anoctamin 1) • MAML2 (Mastermind Like Transcriptional Coactivator 2) • SCGB2A2 (Secretoglobin Family 2A Member 2)
    |
    HER-2 expression
    1year
    The landscape of immunogenic cell death-related genes predicts the overall survival and immune infiltration status of non-small-cell lung carcinoma. (PubMed, Heliyon)
    Our researchers utilized a gene model to analyze the immune inflammation and prognosis of patients with non-small-cell lung cancer (NSCLC). The discovery of new ICD-related genes could lead to the development of new targeted treatments for this condition.
    Journal • IO biomarker
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • FGFR4 (Fibroblast growth factor receptor 4) • MMP1 (Matrix metallopeptidase 1) • SCGB2A2 (Secretoglobin Family 2A Member 2) • UGT2B17 (UDP Glucuronosyltransferase Family 2 Member B17)
    1year
    Understanding the relationship between silicone implants, tumor antigens, and breast cancer risk: An immunological study in rats. (PubMed, Int Immunopharmacol)
    Additionally, laser speckle blood flow imaging and immunohistochemical analysis revealed blood perfusion in the implant capsule area and an active response of immune cells, indicating that immune surveillance may exert local effects. These findings provide the first evidence of a relationship between tumor antigens, silicone implants, and breast cancer incidence, offering a new immunological perspective on the safety of silicone implants.
    Preclinical • Journal
    |
    MUC1 (Mucin 1) • SCGB2A2 (Secretoglobin Family 2A Member 2)